NanoGuardian Provides NanoEncryption Technology to Capsugel
NanoGuardian (Skokie, IL) enters into a license agreement with Capsugel (Peapack, NJ), a division of Pfizer Inc., to provide Capsugel global access to NanoGuardian’s NanoEncryption technology for the protection of capsule-based medications against counterfeiting and illegal diversion. NanoGuardian’s NanoEncryption technology works directly on capsules, tablets, vial caps, and singleuse syringes to provide a layered security strategy consisting of overt, covert and forensic security features.
NanoGuardian’s multi-layered security provides a dual-protective benefit to manufacturers by fighting counterfeiting and illegal diversion with a single technology. The overt and covert security features allow dose-level authentication at any point in a manufacturer’s supply chain, while forensic NanoCodes provide comprehensive tracing information on each and every dose. NanoGuardian’s technology provides a strong benefit compared with other on-dose technologies given that NanoGuardian’s security features are implemented with no additional chemicals being added to the medication.
“Capsugel is committed to providing cutting-edge advancements in capsule dosage delivery technology,” says Guido Driesen, president and general manager of Capsugel. “Given the concerning rise in counterfeit and illegally diverted medications throughout the world, we wanted to bring value to our customers by helping to protect their brands, companies, and the patients they serve. After evaluating available security technologies, we chose NanoGuardian as a technology partner because of the sophistication, sustainability and benefits of their NanoEncryption technology. This will allow our pharmaceutical customers to authenticate and trace every single dose, from plant topatient.”
In addition to the traditional NanoGuardian model of using a proprietary machine to implement the NanoEncryption technology, Capsugel will offer pre-NanoEncrypted capsule shells to pharmaceutical companies, eliminating any significant additions to their current manufacturing process. Capsugel will market this new technology to current and future Capsugel customers and expects it to be able to supply NanoEncrypted capsules by mid-2010.
“NanoGuardian is a leader in the on-dose brand protection marketplace so it makes perfect sense for us to partner with the global leader in capsule-delivery systems,” says James Hussey, CEO, NanoGuardian. “Together, NanoGuardian and Capsugel can extend product security and integrity to the dose level for capsule-based medications and help NanoGuardian and Capsugel announce global partnership provide confidence to the millions of patients who rely on these medications for their health and well being.”
NanoGuardian, a division of NanoInk, focuses exclusively on delivering brand protection solutions to fight illegal diversion and counterfeiting. Capsugel, a division of Pfizer Inc., provides innovative dosage forms and solutions for the healthcare industry.